HALO stock news today

Leerink Partners downgraded Halozyme Therapeutics (HALO) to Market Perform from Outperform and raised its price target to $117 from $110.

Citizens JMP kept its Market Outperform rating on Halozyme Therapeutics (HALO) and raised its price target to $149 from $93.

Evercore ISI kept its Outperform rating on Halozyme Therapeutics (HALO) with a price target of $125.

Wells Fargo kept its Equal-Weight rating on Halozyme Therapeutics (HALO) and raised its price target to $110 from $95.

J.P. Morgan kept its Neutral rating on Halozyme Therapeutics (HALO) and raised its price target to $79 from $78.

TD Cowen kept its Buy rating on Halozyme Therapeutics (HALO) and raised its price target to $130 from $105.

J.P. Morgan kept its Neutral rating on Halozyme Therapeutics (HALO) with a price target of $78.

HC Wainwright & Co. kept its Buy rating on Halozyme Therapeutics (HALO) and raised its price target to $130 from $115.

HC Wainwright & Co. kept its Buy rating on Halozyme Therapeutics (HALO).

What is the latest news on HALO?

Nov 6, 2026: Leerink Partners downgraded Halozyme Therapeutics (HALO) to Market Perform from Outperform and raised its price target to $117 from $110. (Leerink Partners) · Nov 6, 2026: Citizens JMP kept its Market Outperform rating on Halozyme Therapeutics (HALO) and raised its price target to $149 from $93. (Citizens JMP) · Nov 6, 2026: Evercore ISI kept its Outperform rating on Halozyme Therapeutics (HALO) with a price target of $125. (Evercore ISI)

What are analysts saying about HALO?

Nov 6, 2026: Leerink Partners downgraded Halozyme Therapeutics (HALO) to Market Perform from Outperform and raised its price target to $117 from $110. · Nov 6, 2026: Citizens JMP kept its Market Outperform rating on Halozyme Therapeutics (HALO) and raised its price target to $149 from $93. · Nov 6, 2026: Evercore ISI kept its Outperform rating on Halozyme Therapeutics (HALO) with a price target of $125.